Replies to post #209 on Equity Field Notes from temporal sources

[DanWebzster]

BIOAF is focused on blood-brain-barrier (BBB) penetrating technology that can be attached to existing therapeutics.

The MedImmune division of AZN has independently validated their platform

The problem is that the company only has a cash runway into early 2019, leaving them short of the ability to initiate a Ph1 study for their lead program.

Presently, BIOAF is preparing for a Pre-IND meeting for its lead program, HER 2+ Brain Metastases therapy.

The easiest solution to financing the company into the clinic would be a NASDAQ IPO. To qualify, the company was reverse split and raise capital to meet NAZ requirements.

[DanWebzster]

KDMN ( scientific backgrounder)

KDMN focus is on Roh Kinases. Roh Kinases are differentiated in their ability to regulate cytoskeletons.

Roh Kinases are referred to colloquially as either ROCK-1 and ROCK-2

ROCK-1 are active in cytoskeleton destruction throughout the body, but especially in liver, spleen and kidney.

ROCK-2 are active in brain and muscle development and stabilization.

KDO25 is KDMN's in-licensed ROCK Inhibitor that KDMN has made more selective to ROCK-2 inhibition. Theoretically, these changes have made this ROCK Inhibitor therapeutic against fibrotic diseases.